Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2005
10/20/2005WO2005060573A3 Pna-neamine conjugates and methods for producing and using the same
10/20/2005WO2005049800A3 Methods for screening for agents capable of modulating t lymphocyte function in response to a herpes simplex virus-infected cell
10/20/2005WO2005049061A3 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
10/20/2005WO2005045428A3 Methods and compositions for modulating apoptosis
10/20/2005WO2005041901A3 Therapeutics using somatostatin agonists
10/20/2005WO2005041756A3 Skin test for detecting non-allergic hypersensitivity
10/20/2005WO2005040208A3 Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
10/20/2005WO2005040180A3 Antisense modulation of superoxide dismutase 1, soluble (sod-1) expression
10/20/2005WO2005035525A3 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
10/20/2005WO2005033694A3 Novel antisense oligomers and use thereof
10/20/2005WO2005030794B1 Hemiasterlin derivatives and uses thereof
10/20/2005WO2005027954A3 Sincalide formulations
10/20/2005WO2005021494A3 D-amino acid peptides
10/20/2005WO2005016244A3 Methods and compositions for the treatment of gastrointestinal disorders
10/20/2005WO2004103389A3 Means for preventing and treating cellular death and their biological applications
10/20/2005WO2004103266A8 Protein kinase c peptides for use in withdrawal
10/20/2005WO2004090103A3 Identification of novel nogo-receptors and methods related thereto
10/20/2005WO2004064785A3 Cancer therapy sensitizer
10/20/2005WO2004028481A3 Nucleoside derivatives for treating hepatitis c virus infection
10/20/2005WO2003002094A8 Enhanced pharmacokinetic profile of hydrophobic substances
10/20/2005US20050235374 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
10/20/2005US20050235367 Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells and uses thereof
10/20/2005US20050234230 formed via reductive amination with O-[2-(2-aminooxy-ethoxy)-ethyl]-hydroxyl amine; conjugated to erythropoietin
10/20/2005US20050234226 Persephin and related growth factors
10/20/2005US20050234221 genetic vectors, host cells and nucleotide sequences that code polypeptides, agonists and antagonists, that preferentially bind to interleukins, used for diagnosis oro prophylaxis of diseases
10/20/2005US20050234089 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
10/20/2005US20050234073 in mammals by administering drugs which inhibits the expression or activity of microsomal triglyceride transfer proteins; antiinflammatory agents; enzyme inhibitors; reducing direct transfer of phosphatides or lipid to cd antigens
10/20/2005US20050234041 Substituted 1-benzazepines and derivatives thereof
10/20/2005US20050234017 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
10/20/2005US20050234007 RNA interference mediating small RNA molecules
10/20/2005US20050234006 RNA interference mediating small RNA molecules
10/20/2005US20050234005 Cloning and expression of the full length 110 KDa antigen of Orientia tsutsugamushi to be used as a vaccine component against scrub typhus
10/20/2005US20050234001 Methods and compositions for modulating gluconeogenesis using PGC-1
10/20/2005US20050233997 RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
10/20/2005US20050233992 Regeneration of endogeneous myocardial tissue by induction of neovascularization
10/20/2005US20050233991 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
10/20/2005US20050233990 Anti-cancer agents comprising disintegrin genes and the treating methods
10/20/2005US20050233981 Compounds with growth hormone releasing properties
10/20/2005US20050233980 CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
10/20/2005US20050233979 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid
10/20/2005US20050233977 form active ester by the reaction of N-terminal protected alanine, triphenylphosphine and hexachloroethane; reacting with glutamine and deprotecting to give dipeptide
10/20/2005US20050233976 Therapeutic methods
10/20/2005US20050233975 Enone cancer therapeutics
10/20/2005US20050233974 Treating infectious diseases using ice inhibitors
10/20/2005US20050233973 Tri-peptides for antidepressant applications
10/20/2005US20050233971 A hexapeptide contains 4-hydroxyphenylglycine, threonine and phenylalanine units with branched amino groups; cyclic peptides; infection is caused by Bacillus, Clostridium, Staphylococcus, Streptococcus, Enterococcus, Mycobacterium; binds to a structural motif of a pyrophosphates
10/20/2005US20050233970 Methods for treating long QT syndrome
10/20/2005US20050233969 Analogues of GLP-1
10/20/2005US20050233968 Polyamino acid-based insulin preparation
10/20/2005US20050233967 Compositions, systems, and methods for focusing a cell-mediated immune response
10/20/2005US20050233966 Methods for controlling angiogenesis and cell proliferation
10/20/2005US20050233965 regulating vascular permeability. A peptide inhibitor of p21-activated kinase has been found to inhibit the increase in vascular permeability induced by several factors. The present invention further provides methods of identifying regulators of vascular permeability.
10/20/2005US20050233964 Chimeric VEGF peptides
10/20/2005US20050233963 Heat shock response and virus replication
10/20/2005US20050233962 Administering vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), basic fibroblast growth factor or functional fragment or nucleic acid encoding these
10/20/2005US20050233961 Methods for treating cancer using vascular endothelial cell growth inhibitor VEGI-192A
10/20/2005US20050233960 Methods and compositions for inhibiting c-met dimerization and activation
10/20/2005US20050233959 Use of MDA-7 to inhibit pathogenic infectious organisms
10/20/2005US20050233958 Using tumor necrosis factor receptor to identify modulators for prevention and treatment of cell proliferative disorders
10/20/2005US20050233957 Sodium channel regulators and modulators
10/20/2005US20050233956 Proteins involved in the regulation of energy homeostasis
10/20/2005US20050233955 Stimulation of nerve cell regeneration
10/20/2005US20050233954 Use of resistin to treat hematopoietic disorders
10/20/2005US20050233953 Histogranin-like peptides, processes for their preparation and uses thereof
10/20/2005US20050233952 Peptide structure containing lanthionine and methyllanthionine as constituents isolated from Microbispora sp. ATCC PTA-5024; methicillin resistant and vancomycin resistant bacteria; M. catharralis, Neisseria species and H. influenzae and Mycobacteria
10/20/2005US20050233951 Novel two gonadotropin releasing hormones and a method to isolate the same
10/20/2005US20050233950 Synergistic antimicrobial compositions and methods for reducing biofilm formation
10/20/2005US20050233949 Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof
10/20/2005US20050233948 Drug complex for treatment of metastatic prostate cancer
10/20/2005US20050233947 Combinations of chromium or vanadium with antidiabetics
10/20/2005US20050233946 Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
10/20/2005US20050233945 Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation
10/20/2005US20050233943 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
10/20/2005US20050233942 Oxygenated dibenzo-alpha-pyrone chromoproteins
10/20/2005US20050233941 Pin coated assay
10/20/2005US20050233443 Restenosis therapy using mesenchymal stem cells
10/20/2005US20050233419 Cleaving chondroitin sulfate with a modified chondroitinase B having the amino acid sequence of the mature peptide; modifying with individual residues involved in substrate binding and catalysis
10/20/2005US20050233413 Neuroprotective polypeptides and methods of use
10/20/2005US20050233412 An artificial mutant tRNA synthetase; aminoacylates an orthogonal tRNA with beta -GlcNAc-serine
10/20/2005US20050233411 Compositions and methods for cleaving IAP
10/20/2005US20050233408 Modified bacterial surface layer proteins
10/20/2005US20050233402 Heparinase III HLGAG fragments and uses thereof
10/20/2005US20050233387 Assay method
10/20/2005US20050233385 Using antibodies on cell surfaces
10/20/2005US20050233383 Human olfactory receptors and genes encoding same
10/20/2005US20050233379 Methods of antagonizing morphogens
10/20/2005US20050233375 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
10/20/2005US20050233374 Reagents and methods useful for detecting diseases of the prostate
10/20/2005US20050233359 Isolated nucleic acid molecule encoding a neurotrophic growth factor
10/20/2005US20050233347 Can be used for the treatment of diabetes or for delaying the onset of diabetes
10/20/2005US20050233344 RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
10/20/2005US20050233341 Using single nucleotide polymorphism in fucose-1-phosphate guanylyltransferase (FPGT) and cyclin dependent kinase kinesin genes as diagnostic indicators of cell proliferative disorders; antitumor agents; ribozymes and tumor treatment; RNA interference
10/20/2005US20050233328 Methods of identifying compounds that modulate protein activity
10/20/2005US20050233323 Novel protein and dna thereof
10/20/2005US20050233316 Monoclonal antibody for diagnosis, prevention and treatment of viral infections; immunotherapy
10/20/2005US20050233304 Method of screening remedy for renal failure
10/20/2005US20050233060 Protein isolated from animal muscle; filtrating acidic protein; heating; gelation
10/20/2005US20050233003 Nanosized particles of salicylic acid wrapped in an amphiphilic polymer of polyacrylic acid, polyacrylamide, polymethacrylamide and polylysine; polymer is modified with urea, nicotinamide or guanidine
10/20/2005US20050232997 Pharmaceutical formulations
10/20/2005US20050232981 Compositions capable of facilitating penetration across a biological barrier
1 ... 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 ... 3163